SCHEMBL6309072

SCHEMBL6309072

O=C1CCCc2ccc(OCc3ccc(Cl)cc3)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAOB P27338 19/20 1.00
MAOA P21397 18/20 1.00
HPD P32754 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20572760 0.89 MAOB (1.00) MAOBMAOA
SCHEMBL7566856 0.87 MAOB (0.77) MAOBMAOA
SCHEMBL30067289 0.86 MAOB (1.00) MAOBMAOA
SCHEMBL3501723 0.86 MAOB (1.00) MAOBMAOA
SCHEMBL7215662 0.86 MAOB (0.94) MAOBMAOA
SCHEMBL6308414 0.86 MAOB (0.82) MAOBMAOA
SCHEMBL7222729 0.85 MAOB (0.97) MAOBMAOAHPD
SCHEMBL7184607 0.84 MAOA (0.76) MAOBMAOA
SCHEMBL17332123 0.83 MAOA (0.71) MAOBMAOAHPD
SCHEMBL7218099 0.83 MAOB (0.82) MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080090-A1 Naphthalene derivatives CHENARD BERTRAND L (US) 2005-04-14 US disclosed
US-20020058811-A1 Naphthalene derivatives CHENARD BERTRAND L (US) 2002-05-16 US disclosed
US-20010004669-A1 Pyrazinyl-substituted naphthalene derivatives CHENARD BERTRAND L (US) 2001-06-21 US disclosed
EP-0689536-B1 NAPHTHALENE DERIVATIVES PFIZER (US) 2001-05-23 EP disclosed
EP-0701819-B1 Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist PFIZER (US) 2000-08-16 EP disclosed
US-5597826-A Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist PFIZER INC. (US) 1997-01-28 US disclosed
EP-0701819-A2 Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist PFIZER INC. (US) 1996-03-20 EP disclosed
EP-0689536-A1 NAPHTHALENE DERIVATIVES PFIZER INC. (US) 1996-01-03 EP disclosed
WO-1994021619-A1 NAPHTHALENE DERIVATIVES PFIZER INC. (US) 1994-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010004669-A1 Pyrazinyl-substituted naphthalene derivatives HTR4, HCRTR2, CNR2 MAOB 128/4885MAOA 349/4885HPD 625/4885
US-20050080090-A1 Naphthalene derivatives HTR4, NPY4R, HCRTR1 MAOB 299/4885MAOA 558/4885HPD 1107/4885
US-20020058811-A1 Naphthalene derivatives HTR4, CNR1, CNR2 MAOB 245/4885MAOA 412/4885HPD 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.